The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157: Miracle Healing Peptide or Hidden Danger? The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions FDA Is Expected to Lift Restriction on Peptides, Heeding RFK Jr.'s Wishes The New York Times An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica